BIOMAT Database Logo BIOMAT Database Logo

[Proceedings: Clinical experiences with a new beta adrenergic blocking agent KO 1366 (0-[2-hydroxy-3-(tertiarybutylamino)-propoxy]-benzonitrile-hydrochloride)]. 1975

S Fujise, and T Takada, and S Osanai, and H Abe

UI MeSH Term Description Entries
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic

Related Publications

S Fujise, and T Takada, and S Osanai, and H Abe
Haemodynamic observations with KO. 1366 (bunitrolol), a new beta-adrenergic blocking agent.
January 1977, Current medical research and opinion,
S Fujise, and T Takada, and S Osanai, and H Abe
[Circulatory effects of a new specific beta adrenergic blocking agent, (o-(2-hydroxy-3-(tert. butylamino)-propoxyl)-benzonitrile, Kö 1366)].
June 1973, Arzneimittel-Forschung,
S Fujise, and T Takada, and S Osanai, and H Abe
Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent beta-adrenergic blocking agent.
December 1974, Japanese journal of pharmacology,
S Fujise, and T Takada, and S Osanai, and H Abe
[Clinical experiences with a new beta-sympatholytic agent Kö 1366 (bunitrolol)].
September 1974, Wiener medizinische Wochenschrift (1946),
S Fujise, and T Takada, and S Osanai, and H Abe
Synthesis of certain 3-[4-[2-hydroxy-3-(isopropylamino) propoxy]phenyl]propionate as beta-adrenergic blocking agents.
January 1987, Journal de pharmacie de Belgique,
S Fujise, and T Takada, and S Osanai, and H Abe
Pharmacology of dl-5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy) coumarin hydrochloride (CS-359), a new beta-adrenergic blocking agent.
August 1973, Japanese journal of pharmacology,
S Fujise, and T Takada, and S Osanai, and H Abe
Effect of o-2-hydroxy-3-(tert.-butylamino) propoxybenzonitrile HCl (KO 1366) on beta adrenergic receptors in the cardiovascular system.
February 1972, The Journal of pharmacology and experimental therapeutics,
S Fujise, and T Takada, and S Osanai, and H Abe
[Adrenergic beta-receptor blocking activity of (3-amino-2-hydroxy)propoxy-3, 4-dihydrocarbostyril derivatives in anesthetized dog (author's transl)].
May 1974, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
S Fujise, and T Takada, and S Osanai, and H Abe
Oxprenolol: clinical experiences with a new beta-adrenergic blocking drug.
January 1970, The Medical journal of Australia,
S Fujise, and T Takada, and S Osanai, and H Abe
[Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent].
February 1968, Arzneimittel-Forschung,
Copied contents to your clipboard!